Neurocrine Biosciences Inc (NBIX)

Add to Watchlists
Create an Alert
Quickflows
103.54 -0.46  -0.44% NASDAQ Oct 22, 16:00 103.51 -0.03  -0.03% After-Hours: 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All NBIX News

News

View All Events

Events

Date Type Description
11/01/2021 Earnings Results Q3 2021 Earnings Results
11/01/2021 16:30 EST Earnings Calls Q3 2021 Earnings Call
08/03/2021 Earnings Results Q2 2021 Earnings Results
08/03/2021 16:30 EST Earnings Calls Q2 2021 Earnings Call
05/19/2021 10:30 EST AGM 2020 Annual General Meeting
05/05/2021 Earnings Results Q1 2021 Earnings Results
05/05/2021 16:30 EST Earnings Calls Q1 2021 Earnings Call
02/04/2021 Earnings Results Q4 2020 Earnings Results
02/04/2021 16:30 EST Earnings Calls Q4 2020 Earnings Call
11/09/2020 Earnings Results Q3 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 1.032B
Total Expenses (TTM) 786.60M
Net Income (TTM) 364.70M

Balance Sheet View Statement

Total Assets (Quarterly) 1.956B
Total Liabilities (Quarterly) 677.20M
Shareholders Equity (Quarterly) 1.279B

Cash Flow Statement View Statement

Cash from Operations (TTM) 264.60M
Cash from Investing (TTM) -150.20M
Cash from Financing (TTM) -161.50M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
  • URL: http://www.neurocrine.com
  • Investor Relations URL: https://www.neurocrine.com/about-us/webcasts-presentations
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Nov. 01, 2021
  • Last Earnings Release: Aug. 03, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Dec. 29, 1995

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 103.54
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
FBT First Trust NYSE Arca Biotech ETF 3.32%
PBE Invesco Dynamic Biotech & Genome ETF 3.14%
DYN1583 Dynamic Power American Growth Cl Ser IP (USD) 2.91%
JFNSX Janus Henderson Global Life Sciences S 1.67%
FBTDX Franklin Biotechnology Discovery C 1.48%
ECHSX Eaton Vance Worldwide Health Sci C 1.39%
GSMQX Goldman Sachs Small/Mid Cap Growth Svc 1.38%
HQH Tekla Healthcare Investors 1.18%
IJK iShares S&P Mid-Cap 400 Growth ETF 0.87%
MDYG SPDR® S&P 400 Mid Cap Growth ETF 0.86%
XBI SPDR® S&P Biotech ETF 0.83%
MSCGX Mercer US Small/Mid Cap Equity Y3 0.76%

Comparables

Edit
SGEN Seagen Inc
AIM AIM ImmunoTech Inc
PLX Protalix BioTherapeutics Inc
ARMP Armata Pharmaceuticals Inc
ELMD Electromed Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.